255 related articles for article (PubMed ID: 8939141)
41. [Report from the Satellite Symposium: Leading the way: outstanding efficacy of interferon beta-1b right from the start. Berlin, Germany, 06.24.2002].
Cendrowski W
Neurol Neurochir Pol; 2002; 36(6):1260-3. PubMed ID: 12715704
[No Abstract] [Full Text] [Related]
42. [Interferon beta-1b in multiple sclerosis--news regarding open questions].
Nervenarzt; 1997 Aug; 68(8 Suppl Interferon):1-4. PubMed ID: 9380220
[No Abstract] [Full Text] [Related]
43. Therapeutic expectations of patients with multiple sclerosis upon initiating interferon beta-1b: relationship to adherence to treatment.
Mohr DC; Goodkin DE; Likosky W; Gatto N; Neilley LK; Griffin C; Stiebling B
Mult Scler; 1996 Dec; 2(5):222-6. PubMed ID: 9050360
[TBL] [Abstract][Full Text] [Related]
44. Interferon beta treatment for multiple sclerosis: persisting questions.
Goodkin DE
Mult Scler; 1996 Jul; 1(6):321-4. PubMed ID: 9345408
[TBL] [Abstract][Full Text] [Related]
45. Treating multiple sclerosis with vitamin D.
Chataway J
J Neurol Neurosurg Psychiatry; 2012 May; 83(5):473. PubMed ID: 22410370
[No Abstract] [Full Text] [Related]
46. Multiple sclerosis therapy. A practical guide.
van Oosten BW; Truyen L; Barkhof F; Polman CH
Drugs; 1995 Feb; 49(2):200-12. PubMed ID: 7729328
[TBL] [Abstract][Full Text] [Related]
47. Anaphylactoid reaction to methyl prednisolone developing after starting treatment with interferon beta-1b.
Clear D
J Neurol Neurosurg Psychiatry; 1999 May; 66(5):690. PubMed ID: 10348645
[No Abstract] [Full Text] [Related]
48. [Side-effects of the treatment with disease modifying drugs in patients with multiple sclerosis: an analysis of register data in the Yaroslavl region].
Spirin NN; Kasatkin DS; Stepanov IO; Shipova EG; Baranova NS
Zh Nevrol Psikhiatr Im S S Korsakova; 2012; 112(8):27-33. PubMed ID: 23096035
[TBL] [Abstract][Full Text] [Related]
49. Recurrent nephrotic syndrome in patient with multiple sclerosis treated with interferon beta-1a.
Tola MR; Caniatti LM; Gragnaniello D; Russo M; Stabellini N; Granieri E
J Neurol; 2003 Jun; 250(6):768-9. PubMed ID: 12862038
[No Abstract] [Full Text] [Related]
50. To treat, or not to treat: the therapeutic dilemma of idiopathic monosymptomatic demyelinating syndromes.
Frohman EM; Racke M; van Den Noort S
Arch Neurol; 2000 Jul; 57(7):930-2. PubMed ID: 10891973
[No Abstract] [Full Text] [Related]
51. Time-course analysis of CD25 and HLA-DR expression on lymphocytes in interferon-beta 1b-treated multiple sclerosis patients.
Ferrarini AM; Sivieri S; Buttarello M; Facchinetti A; Perini P; Gallo P
Mult Scler; 1998 Jun; 4(3):174-7. PubMed ID: 9762669
[TBL] [Abstract][Full Text] [Related]
52. Immunotherapy for MS: clinical aspects and trials.
Ebers GC; Sibley WA; Paty DW
Acta Neurol Scand Suppl; 1995; 161():54. PubMed ID: 7653246
[No Abstract] [Full Text] [Related]
53. Multiple sclerosis pathways: an innovative nursing role in disease management.
Madonna MG; Keating MM
J Neurosci Nurs; 1999 Dec; 31(6):332-5. PubMed ID: 10726241
[TBL] [Abstract][Full Text] [Related]
54. Interferon beta-1a and beta-1b for treatment of multiple sclerosis.
Kappos L
Lancet; 2002 Nov; 360(9343):1428; author reply 1428-9. PubMed ID: 12424020
[No Abstract] [Full Text] [Related]
55. Interferon beta in the treatment of multiple sclerosis--closing remarks.
Kappos L
Mult Scler; 1995; 1 Suppl 1():S64-6. PubMed ID: 9345403
[No Abstract] [Full Text] [Related]
56. [Satellite decade symposium of achievements and the future of multiple sclerosis treatment. 19. Congress ECTRIMS, Mediolan (Italy), September 19, 2003].
Cendrowski W
Neurol Neurochir Pol; 2004; 38(1):73-4. PubMed ID: 15049175
[No Abstract] [Full Text] [Related]
57. Panniculitis and lipoatrophy after subcutaneous injection of interferon beta-1b in a patient with multiple sclerosis.
O'Sullivan SS; Cronin EM; Sweeney BJ; Bourke JF; Fitzgibbon J
J Neurol Neurosurg Psychiatry; 2006 Dec; 77(12):1382-3. PubMed ID: 16782776
[No Abstract] [Full Text] [Related]
58. Comment on Shuhaibar et al.: Favourable effect of immunomodulator therapy on bone mineral density in multiple sclerosis.
Kampman MT; Steffensen LH
Ir J Med Sci; 2009 Jun; 178(2):235-6; author reply 237-8. PubMed ID: 19184608
[No Abstract] [Full Text] [Related]
59. Beta interferon and multiple sclerosis: why the fuss?
Mumford CJ
QJM; 1996 Jan; 89(1):1-3. PubMed ID: 8730337
[No Abstract] [Full Text] [Related]
60. Interferon beta in multiple sclerosis.
Arnason BG
Clin Immunol Immunopathol; 1996 Oct; 81(1):1-11. PubMed ID: 8808634
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
